Skip to main content
Premium Trial:

Request an Annual Quote

Ionpath Closes $18M Series B Round

NEW YORK – Spatial proteomics firm Ionpath said on Thursday that it has closed an $18 million Series B financing round.

Led by Samsara BioCapital, the round also included new investor Bruker, whose MALDI mass spectrometry imaging platforms could have synergies with Ionpath's Multiplexed Ion Beam Imaging (MIBI) technology, Rohan Thakur, executive VP at Bruker, said in a statement.

Existing investors including Genoa Ventures, ND Capital, Paladin Partners Investments, Trancos Ionpath Investors, Norwich Ventures, and Vertical Venture Partners Growth Fund also contributed to the round.

"Developed by pathologists for translational researchers, Ionpath’s MIBI platform delivers a revolutionary way to visualize phenotypic profiles, enabling rich, sensitive spatial analysis of tissue microenvironments," Mike Dybbs, partner at Samsara BioCapital and Ionpath board member, said in a statement. "We are excited to support Ionpath in its mission to advance precision medicine and we are proud to partner with Bruker and all the company’s investors on this financing."

"We are seeing strong traction for our MIBI technology, both in our MIBIscope instrument and our end-to-end Research Services business. We are more convinced than ever that MIBI-enabled, high-definition spatial proteomics will be a key enabler for the deployment of precision medicine in the treatment of a wide range of diseases," said Ionpath CEO Sander Gubbens.